Petefészekrák: vizsgálatok itt: Tajvan
32 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Where
- Taichung, Tainan, Taipei, Taoyuan
- Életkor
- 18 év and over
- People
- 770 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06824467 · EU 2023-508015-23-00 - 1/2. fázisTaking peopleA Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
- Where
- Taipei, Taoyuan
- Életkor
- 18 év and over
- People
- 605 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06843447 · EU 2024-514674-47-00 - 3. fázisTaking peopleA Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Where
- Taichung, Tainan, Taipei, Taoyuan
- Életkor
- 18 év and over
- People
- 900 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07318558 · EU 2023-508047-40-00 - 3. fázisTaking peopleA Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)
- Where
- Tainan
- Életkor
- 18 év and over
- People
- 646 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07743164 · EU 2025-525130-59-00 - 3. fázisTaking peopleA Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
- Where
- Taichung, Taipei
- Életkor
- 18 év and over
- People
- 420 worldwide
- Run by
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
See details and how to joinNCT07546500 - 2. fázisTaking peopleInvestigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- Where
- Changhua, Tainan, Taipei
- Életkor
- 18 év and over
- People
- 397 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06787612 · EU 2024-517806-27-00 - 3. fázisTaking peopleTorvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
- Where
- Kaohsiung City, New Taipei City, Taichung, Tainan, Taipei, Taoyuan
- Életkor
- 18 év and over
- People
- 950 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07851025 · EU 2026-526895-22-00 - 3. fázisTaking peopleA Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
- Where
- Tainan
- Életkor
- 18 év and over
- People
- 802 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07776691 · EU 2025-524592-22-00 - 3. fázisTaking peopleA Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Where
- Kaohsiung Niao Sung Dist, Taichung, Tainan, Taipei, Taoyuan
- Életkor
- 18 év and over
- People
- 1630 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07213804 · EU 2025-522255-25-00 - 2. fázisTaking peopleDB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- Where
- Taipei
- Életkor
- 18 év and over
- People
- 750 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00 - 3. fázisTaking peopleStudy of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Where
- Kaohsiung City, Taichung, Tainan, Taipei, Taoyuan City
- Életkor
- 18 év and over
- People
- 582 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06819007 · EU 2024-516982-35-00 - 2/3. fázisTaking peopleA Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Where
- Taichung, Tainan, Taipei, Taoyuan City
- Életkor
- 18 év and over
- People
- 860 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06161025 · EU 2023-507914-28-00 - 2. fázisTaking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Kaohsiung City, Taichung, Tainan, Taipei, Taoyuan
- Életkor
- 18 év and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - 1/2. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Taichung, Tainan, Taipei
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - 1/2. fázisTaking peopleA Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Where
- Kaohsiung City, New Taipei City, Taipei, Taoyuan
- Életkor
- 18 év and over
- People
- 862 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT05914116 - 3. fázisTaking peopleTorvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
- Where
- Kaohsiung City, Taichung, Tainan, Taipei
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07816666 · EU 2026-526776-23-00 - 1. fázisTaking peopleStudy to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- Where
- Kaohsiung City, Taichung, Taipei, Taoyuan City
- Életkor
- 18 év and over
- People
- 325 worldwide
- Run by
- AbbVie
See details and how to joinNCT06084481 · EU 2023-506227-29-00 - 1/2. fázisTaking peopleA Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Where
- Taichung, Tainan, Taipei, Taoyuan
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01 - 1. fázisTaking peopleA Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
- Where
- Taipei
- Életkor
- 18 év and over
- People
- 285 worldwide
- Run by
- AbbVie
See details and how to joinNCT07278336 · EU 2025-522209-40-00 - 1/2. fázisTaking peoplePhase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Where
- Taichung, Tainan, Taipei
- Életkor
- 18 év to 130 év
- People
- 622 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05797168 · EU 2022-502576-23-00 - 2. fázisTaking peopleStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Where
- Liou Ying Township, Taipei, Taoyuan
- Életkor
- 18 év to 130 év
- People
- 454 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00 - No phaseTaking peopleOvarian Cancer Identification on CT Using Deep Learning
- Where
- Taoyuan, Taoyuan City
- Életkor
- 20 év and over
- People
- 12 578
- Run by
- Chang Gung Memorial Hospital
See details and how to joinNCT06851429 - 3. fázisTaking peopleAZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- Where
- Changhua, New Taipei City, Taichung, Tainan, Taipei, Taoyuan
- Életkor
- 18 év and over
- People
- 1100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07218809 · EU 2025-520466-22-00 - 1. fázisTaking peopleA Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Where
- Kaohsiung City, Taipei
- Életkor
- 18 év and over
- People
- 1006 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT04389632 · EU 2023-508469-34-00 - 1. fázisTaking peopleStudy to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Where
- New Taipei City, Tainan, Taipei
- Életkor
- 18 év and over
- People
- 694 worldwide
- Run by
- AbbVie
See details and how to joinNCT05005403